clinical trial · NCT04614441
NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib
Boehringer Ingelheim·—·completed·n = 214
Idiopathic Pulmonary FibrosisOFEV®
brief summary
To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD) patients treated with nintedanib and biomarkers associated with the disease course, a non-interventional, 3-year, prospective study will be conducted to collect the long-term real-world clinical data on IPF/SSc-ILD/PF-ILD patients newly administered with nintedanib in Taiwan
started
Jan 21, 2021
primary completion
May 14, 2025
completion
May 14, 2025
last updated
Aug 19, 2025
official title
Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol